Guided Therapeutics (GTHP) Payables (2016 - 2025)
Historic Payables for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $2.8 million.
- Guided Therapeutics' Payables rose 1997.42% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 1997.42%. This contributed to the annual value of $2.2 million for FY2024, which is 892.68% up from last year.
- As of Q3 2025, Guided Therapeutics' Payables stood at $2.8 million, which was up 1997.42% from $2.7 million recorded in Q2 2025.
- In the past 5 years, Guided Therapeutics' Payables registered a high of $3.2 million during Q1 2022, and its lowest value of $1.9 million during Q1 2024.
- Over the past 5 years, Guided Therapeutics' median Payables value was $2.3 million (recorded in 2021), while the average stood at $2.4 million.
- Its Payables has fluctuated over the past 5 years, first soared by 2696.1% in 2022, then tumbled by 3126.36% in 2023.
- Over the past 5 years, Guided Therapeutics' Payables (Quarter) stood at $2.5 million in 2021, then decreased by 11.1% to $2.2 million in 2022, then fell by 8.6% to $2.0 million in 2023, then rose by 8.93% to $2.2 million in 2024, then increased by 25.08% to $2.8 million in 2025.
- Its Payables stands at $2.8 million for Q3 2025, versus $2.7 million for Q2 2025 and $2.2 million for Q1 2025.